Clinical trial NCT06918925: First-In-Human Study to Evaluate Single Ascending Doses of JUV-161 in Healthy Adult Volunteers
Official title: A Double-Blind, Placebo-Controlled, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of JUV-161 Administered Subcutaneously to Healthy Adult Volunteers
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Healthy Volunteer
Lead sponsor: Juvena Therapeutics
Sponsor class: INDUSTRY
First posted: 2025-04-09
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: double-blind, placebo controlled
Primary purpose: TREATMENT

Brief summary: The present First-In-Human (FIH) study (JUV-161-101) aims to assess the safety, tolerability, and pharmacokinetics (PK) of single subcutaneous (SC) doses of JUV-161 in healthy volunteers. The study design is well-established for FIH studies and appropriate to assess the preliminary safety and tolerability of new drug candidates.

Data from this study will support conduct of a multiple-ascending dose (MAD) study in patients with DM1 as well as supporting studies in other degenerative myopathies and other disorders for which preclinical efficacy data have been obtained.JUV-161 has not been previously been administered to human subjects.

Detailed description: This is a FIH, randomized, double-blind, placebo-controlled, single-ascending dose (SAD) study. The study will be conducted at a single center and will include healthy volunteer subjects.

Enrollment will include up to 5 cohorts of 8 healthy adult volunteer subjects each of whom will receive a single dose of study drug (JUV-161, n=6; placebo, n=2).

For dosing, consideration of all relevant information obtained from in vitro and nonclinical toxicity studies was used to estimate no observed adverse effect levels (NOAELs) and a human equivalent dose (HED). Data from a 1-month non-human primate (cynomolgus monkeys) GLP study indicated that the NOAEL (HED) was ≥ 10 mg/kg. Using data from this study, modeling predicts that in humans the time to maximal concentration (Tmax) of JUV-161 will be 30-36 hours and the expected half-life (T1/2) of JUV-161 in humans will be approximately 80 hours.

Based on this information, the planned starting dose of JUV-161 0.10 mg/kg was selected to mitigate known, unknown or theoretical risks associated with administration of JUV-161. Sentinel dosing will be implemented within each cohort as an additional safety measure to enable detection of possible acute safety risk(s).

In each cohort, 2 subjects (1 JUV-161 and 1 placebo) will receive Study Drug on Study Day 1 (sentinel dosing). Following administration of study drug, a 72-hour period will be observed to detect the occurrence of reactions or significant adverse events (AEs). If safety and tolerability results are acceptable, 3 subjects will be dosed on Study Day 4. Following an additional 72-hour period and assuming no significant safety issues are identified, the final 3 subjects will be dosed on Study Day 7.

A Safety Review Committee (SRC) will conduct two Safety Reviews per dosing Cohort.

On Study Day 3 of each Cohort, the DMC SRC will review available clinical (including adverse events) and laboratory data from the Sentinel Dosing group to assess initial safety and tolerability of study drug. Assuming no safety issues are identified, dosing will proceed as described above.

On Study Days 28 through 35 of each Cohort, after completion of dosing for each subject in the Cohort, the SRC will review available clinical (including adverse events) and laboratory data to assess initial safety and tolerability of study drug. The review will include clinical, laboratory and (as available) pharmacokinetic data through 20 days after administration of Study Drug to the final 3 subjects in the Cohort. This period includes, and extends beyond, the predicted 5 half-lives of serum concentration following administration of JUV-161 for all subjects. Assuming no safety issues are identified, dosing for the subsequent Cohort may be initiated.

Additional study cohorts may be added, pending approval by the SRC, if the Sponsor believes additional dosing, safety, or pharmacokinetic data are required.

Eligibility criteria: Inclusion Criteria:

1. Are males or nonpregnant females, ages 18 to 60 (inclusive) at time of signing Informed Consent with body mass index (BMI) 18 to 35 kg/m2
2. Are willing and able to give informed consent and follow all study procedures and requirements
3. Are able to understand the requirements of the study protocol
4. Agree to complete all required study visits
5. Are healthy, based on physical examination, medical history laboratory tests, vital signs and resting electrocardiograms
6. Are willing to abstain from caffeine and nicotine while in the Study Unit
7. Have negative screens for alcohol and drugs of abuse at screening and admission
8. Are willing to abstain from all alcoholic beverages and cannabinoids for 48 h prior to dosing through Post-dosing visit on Study Day 6.
9. Females must be either:

   * of non-childbearing potential (defined as having undergone surgical sterilization (hysterectomy, bilateral salpingectomy, bilateral oophorectomy or being postmenopausal (i.e., greater than 45 years old with amenorrhea for ≥ 12 months).) \[Women under the age of 55 years must have a follicle stimulating hormone (FSH) level \> 40mIU/mL to confirm menopause\] OR
   * of child-bearing potential and using at least one of the following acceptable methods of contraception from at least 30 days prior to the time of informed consent through the time of study drug administration and for 8 weeks after last administration of study drug:

     1. Hormonal methods of contraception, including oral contraceptives containing combined estrogen and progesterone, a vaginal ring, injectable and implantable hormonal contraceptives, intrauterine hormone-releasing system (e.g., Mirena) and progestogen-only hormonal contraception associated with inhibition of ovulation
     2. Nonhormonal intrauterine device (IUD)
     3. Bilateral tubal occlusion
     4. Vasectomized subject/partner with documented azoospermia 90 days after procedure, if that partner is the sole sexual partner NOTE: WOCBP who are not exclusively in same-sex relationships must agree to use adequate contraception. WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements. However, WOCBP must still undergo pregnancy testing as per protocol.

   NOTE: Complete abstinence, defined as the complete avoidance of heterosexual intercourse - is an acceptable form of contraception if used consistently throughout the duration of study and for the durations after dosing specified for males and females above. It is not necessary to use any other method of contraception when complete abstinence is elected. WOCBP who choose complete abstinence must continue to have pregnancy tests as per protocol. The reliability of sexual abstinence needs to be evaluated by the Investigator in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.

   NOTE: Female subjects must avoid egg donation from Screening through at least 2 months after administration of the last dose of study drug.
10. Men who are sexually active and males with partners of child-bearing potential must use the following forms of medically acceptable birth control during the study drug treatment period and for 16 weeks after the last administration of study drug:

    1. Vasectomy with medical assessment of surgical success and consistent use of a condom OR
    2. Consistent use of a condom with partner also using either stable hormonal contraceptive or IUD.

    NOTE: Males who are continuously not heterosexually active are exempt from contraceptive requirements.

    NOTE: Sperm donation is prohibited during the study and for up to 120 days4 months after the last administration of study drug.
11. Have NOT participated in a clinical study utilizing an investigational agent within 28 days or within 5 half-lives of the investigational drug (whichever is longer) prior to Screening

Exclusion Criteria:

1. Are unwilling or unable to comply with study procedures, including follow-up, as specified by the protocol, or unwilling to cooperate fully with the Investigator
2. Have a history of drug or alcohol abuse within 3 months of Screening
3. Have an active malignancy or have a history of malignancy within the 5 years prior to Screening. (Subjects with prior basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that were successfully treated may be enrolled.)
4. Have any of the following known active infections:

   1. Infection requiring systemic antiviral or antimicrobial therapy that would not have been completed within 30 days prior to screening
   2. Known history or positive test result for HIV, HBV or HCV
5. Have any clinical history or other active medical condition, psychiatric disorder or clinically significant laboratory abnormality, vital sign, ECG abnormality or other finding that, in the investigator's opinion, is likely to increase the risk of study participation, confound study results, or interfere with study conduct or adherence
6. Have any of the following:

   1. History of diabetes
   2. History of bleeding disorder or excessive bleeding
   3. Impaired renal function (estimated glomerular filtration rate \[eGFR\] \<60ml/min/1.73m2, using the CKD-EPI (2021 equation) \[See Appendix 1.\]
   4. Platelet count \< 125 X 109/L
   5. INR \> ULN
   6. Electrocardiogram (ECG) showing QTcF \> 470 msec female or \> 450 msec male
7. Have received

   1. Treatment with any prescription medication within 14 days prior to screening (exception: contraceptives are permitted)
   2. Treatment with any non-prescription medication within 7 days or 5 half-lives (whichever is longer) prior to dosing (exception: acetaminophen up to 2 g per day prior to dosing is permitted)
   3. Any vaccination (therapeutic or prophylactic) within 30 days prior to screening and agree to not receive any vaccination during the course of the study
8. Prior exposure to JUV-161 or have known allergies to any components of the JUV-161 formulation
9. History of immune reaction to any biologic therapy
10. Donation or loss of greater than 1 unit (450 mL) of blood or donation of plasma through plasmapheresis within 7 days prior to screening.

Primary outcomes:
measure: Incidence of treatment-emergent adverse events
timeFrame: From enrollment through to safety follow-up Visit on Day 60
measure: Number of participants with treatment-emergent potentially clinically-significant safety abnormalities in safety laboratory parameters
timeFrame: From enrollment through to safety follow-up Visit on Day 60
measure: Number of participants who have changes from baseline in electrocardiogram values in QTcF intervals
timeFrame: From enrollment through the safety follow-up visit on Day 60
measure: Number of participants who have changes from baseline in heart rate ( beats per minute)
timeFrame: From enrollment through the safety follow-up visit on Day 60
measure: Number of participants who have a change from baseline in systolic and diastolic blood pressure (mmHg)
timeFrame: From enrollment through the safety follow-up visit on Day 60
Secondary outcomes:
measure: Maximum observed plasma concentration (Cmax)
timeFrame: Day 1 pre-dose and at 1, 2, 6, 12, 24, 36, 48, 60 and 72 hours Day 6,8,11,15,18,21 and 60
measure: Time to the maximum measured plasma concentration (Tmax):
timeFrame: Up to 60 days
measure: Area under the concentration-time curve from time zero through to infinity (AUC0-∞)
timeFrame: Up to 60 days.
measure: Terminal elimination half-life in plasma (t1/2)
timeFrame: Up to 60 days
Other outcomes:
Locations:
city: Melbourne
country: Australia
facility: Nucleus Network Pty Ltd
state: Victoria
Study officials:
affiliation: Nucleus Network
name: Philip Ryan, MD
role: PRINCIPAL_INVESTIGATOR
References: